KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$12.00 USD
-0.08 (-0.66%)
Updated May 13, 2024 04:00 PM ET
After-Market: $12.03 +0.03 (0.25%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
KALV 12.00 -0.08(-0.66%)
Will KALV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KALV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KALV
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
KALV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
Here's Why You Should Invest in Alpine (ALPN) Stock Now
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
Other News for KALV
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
KalVista price target lowered by $4 at H.C. Wainwright, here's why
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals: A Strong Buy on Strategic Growth and Promising Sebetralstat Prospects
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year